Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Nouscom

Nouscom
2015 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series B LATEST DEAL TYPE
$49.3M LATEST DEAL AMOUNT
4 INVESTORS
Description

Developer of next generation immunotherapies created to combat cancer by activating cancer-specific T cells. The company's proprietary technology platform, Exovax, harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • B√§umleingasse 18
  • 4051 Basel
  • Switzerland

+41 061 000 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Nouscom’s full profile, request a free trial.

Nouscom Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 06-Nov-2017 $49.3M 000.00 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 17-May-2016 000.00 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Nouscom Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
000 0000000000000 Venture Capital-Backed Chester, United Kingdom 00 000.00 00000000000 000.00
00000 Private Equity-Backed San Diego, CA 00 0000 0000000 0000 0000
000 000000000000 Venture Capital-Backed Epalinges, Switzerland 000 00000 00000000
00000 00000 000000 Venture Capital-Backed Geneva, Switzerland 000 00000 0000000000 0 00000
To view this company’s complete list of competitors, request access »

Nouscom Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
5AM Ventures Venture Capital Minority 000 0000 000000 0
Abingworth Management Venture Capital Minority 000 0000 000000 0
Life Sciences Partners Venture Capital Minority 000 0000 000000 0
Versant Venture Management Venture Capital Minority 000 0000 000000 0

Nouscom Executive Team (9)

Name Title Board
Seat
Contact
Info
Alfredo Nicosia Ph.D Co-Founder, Chief Executive Officer & Board Member
Marina Udier Chief Operating Officer
Stefano Colloca MD Co-Founder & Chief Technical Officer
Elisa Scarselli MD Co-Founder & Chief Scientific Officer
Antonella Folgori Ph.D Co-Founder & Senior Director, Immunology

1 Former Executive

You’re viewing 5 of 9 executives. Get the full list »

Nouscom Board Members (10)

Name Representing Role Since Contact
Info
Alfredo Nicosia Ph.D Nouscom Co-Founder, Chief Executive Officer & Board Member 000 0000
Genghis Lloyd-Harris Ph.D Abingworth Management Board Member 000 0000
Gianni Gromo Ph.D Versant Venture Management Board Observer 000 0000
Guido Magni MD Versant Venture Management Chairman 000 0000
Jean-Paul Prieels Ph.D Self Independant Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 10 board members. Get the full list »